BeiGene Gross Margin 2014-2024 | ONC
Current and historical gross margin for BeiGene (ONC) over the last 10 years. The current gross profit margin for BeiGene as of September 30, 2024 is %.
| BeiGene Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-09-30 |
$3.32B |
$2.78B |
83.75% |
| 2024-06-30 |
$3.10B |
$2.63B |
85.01% |
| 2024-03-31 |
$2.76B |
$2.34B |
84.72% |
| 2023-12-31 |
$2.46B |
$2.08B |
84.58% |
| 2023-09-30 |
$2.20B |
$1.86B |
84.26% |
| 2023-06-30 |
$1.81B |
$1.48B |
81.89% |
| 2023-03-31 |
$1.56B |
$1.25B |
80.49% |
| 2022-12-31 |
$1.42B |
$1.13B |
79.68% |
| 2022-09-30 |
$1.25B |
$0.99B |
78.90% |
| 2022-06-30 |
$1.07B |
$0.84B |
78.11% |
| 2022-03-31 |
$0.88B |
$0.68B |
77.42% |
| 2021-12-31 |
$1.18B |
$1.01B |
85.97% |
| 2021-09-30 |
$1.06B |
$0.93B |
87.10% |
| 2021-06-30 |
$0.95B |
$0.84B |
88.28% |
| 2021-03-31 |
$0.86B |
$0.77B |
89.57% |
| 2020-12-31 |
$0.31B |
$0.24B |
77.02% |
| 2020-09-30 |
$0.27B |
$0.20B |
74.44% |
| 2020-06-30 |
$0.23B |
$0.16B |
70.22% |
| 2020-03-31 |
$0.40B |
$0.33B |
82.84% |
| 2019-12-31 |
$0.43B |
$0.36B |
83.64% |
| 2019-09-30 |
$0.43B |
$0.37B |
85.58% |
| 2019-06-30 |
$0.43B |
$0.38B |
88.25% |
| 2019-03-31 |
$0.24B |
$0.20B |
83.61% |
| 2018-12-31 |
$0.20B |
$0.17B |
84.92% |
| 2018-09-30 |
$0.16B |
$0.14B |
85.44% |
| 2018-06-30 |
$0.32B |
$0.31B |
95.06% |
| 2017-09-30 |
$0.22B |
$0.22B |
99.09% |
| 2016-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2016-03-31 |
$0.01B |
$0.01B |
100.00% |
| 2015-12-31 |
$0.01B |
$0.01B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
